$Cognition Therapeutics (CGTX.US)$ Cognition Therapeutics, Inc. (nasdaq: CGTX) is a clinical-stage company dedicated to developing drugs for the treatment of neurodegenerative diseases, providing an update on the biomarker analysis in the phase 2 'SHINE' study in mild to moderate Alzheimer's disease. This new analysis focuses on plasma samples from all participants entering the study with low levels of plasma P-t217. Several blood-based measurements of Alzheimer's disease biology were normalized in the CT1812 treatment group compared to the placebo group. These biomarker changes are consistent with a 95% slowing in cognitive decline measured by ADAS-Cog11 in the same patients. These data further demonstrate that CT1812 may maintain cognitive function and slow disease progression by protecting critical neural systems.

$DevvStream (DEVS.US)$ I won't buy in because of too much debt.

$SKK Holdings (SKK.US)$
Too many people are trapped.

$SKK Holdings (SKK.US)$ I still encourage you to go $Virpax Pharmaceuticals (VRPX.US)$ 🤣

$Virpax Pharmaceuticals (VRPX.US)$ 1.3,1.8,3.2

$SKK Holdings (SKK.US)$ Be careful not to be trapped again.

$Virpax Pharmaceuticals (VRPX.US)$ Now is a great buying opportunity! bull

$Silexion Therapeutics (SLXN.US)$ Can't climb, 😄

$Gaucho Group (VINO.US)$ coming 300%🤔🤭

$LI-CYCLE (LICY.US)$ There should still be something to watch before the market opens tomorrow 🤔